Synthetic membrane-receiver complexes
Compositions comprising synthetic membrane-receiver complexes, methods of generating synthetic membrane-receiver complexes, and methods of treating or preventing diseases, disorders or conditions therewith.
1. A method of reducing phenylalanine concentration in the blood of a subject, comprising administering to the subject a pharmaceutical composition comprising a plurality of enucleated erythroid cells comprising at least 1,000 copies of an exogenous polypeptide comprising phenylalanine ammonia lyase (PAL), wherein the exogenous polypeptide is not fused to an endogenous polypeptide and is intracellular, wherein each of the enucleated erythroid cells of said plurality was made by a process comprising introducing into an erythroid cell precursor an exogenous nucleic acid encoding the exogenous polypeptide, and wherein none of the enucleated erythroid cells of said plurality is hypotonically loaded.
2. The method of claim 1 , wherein at least one enucleated erythroid cell in the plurality comprises at least 10,000 copies of the exogenous polypeptide.
3. The method of claim 1 , wherein at least one enucleated erythroid cell in the plurality comprises at least 25,000 copies of the exogenous polypeptide.
4. The method of claim 1 , wherein one or more of the enucleated erythroid cells in the plurality resides in circulation for longer than any one of 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10 days.
5. The method of claim 1 , wherein the exogenous polypeptide resides in circulation for substantially the duration of the plurality of enucleated erythroid cells in circulation.
6. The method of claim 1 , wherein the exogenous polypeptide does not substantially diffuse out of the enucleated erythroid cells of the plurality.
7. The method of claim 1 , wherein one or more of the enucleated erythroid cells in the plurality exhibits substantially the same osmotic membrane fragility as an isolated, unmodified, cultured or uncultured erythroid cell.
8. The method of claim 1 , further comprising administering the pharmaceutical composition at least twice.
9. The method of claim 1 , wherein the concentration of phenylalanine in the blood is decreased by at least about 5% after administration.
10. The method of claim 1 , wherein the plurality of enucleated erythroid cells comprises reticulocytes, mature erythrocytes, or both of reticulocytes and mature erythrocytes.
11. The method of claim 1 , wherein at least one enucleated erythroid cell in the plurality lacks A antigen and B antigen.
12. The method of claim 1 , wherein the subject is deficient in phenylalanine ammonia hydroxylase (PAH) activity.
13. The method of claim 12 , wherein the deficiency in PAH activity is associated with a PAH enzyme mutation.
14. The method of claim 1 , wherein the subject has benign hyperphenylalaninemia or phenylketonuria.
15. The method of claim 1 , wherein at least 20% of enucleated erythroid cells in the pharmaceutical composition comprise the exogenous polypeptide.
16. The method of claim 1 , wherein at least one enucleated erythroid cell in the pharmaceutical composition comprises fetal hemoglobin.
17. The method of claim 1 , wherein at least 60% of cells in the pharmaceutical composition are enucleated erythroid cells.
18. The method of claim 1 , wherein the pharmaceutical composition has a reticulocyte to non-reticulocyte ratio of greater than 10.
19. The method of claim 1 , wherein at least one enucleated erythroid cell in the plurality comprises at least 50,000 copies of the exogenous polypeptide.
20. The method of claim 1 , wherein at least one enucleated erythroid cell in the plurality comprises at least 100,000 copies of the exogenous polypeptide.
21. The method of claim 1 , wherein the exogenous nucleic acid comprises DNA.
22. The method of claim 1 , wherein the exogenous nucleic acid comprises RNA.
23. The method of claim 1 , wherein the exogenous polypeptide consists essentially of PAL.
24. The method of claim 1 , wherein the pharmaceutical composition is administered intravenously to the subject.